Vitiligo is a common acquired, autoimmune, and chronic depigmenting skin disease. It not only significantly affects patients'quality of life, but also their mental health. Although there are various treatment options for vitiligo, their efficacy is limited and varies among individuals. As a novel topical JAK inhibitor, ruxolitinib cream is the world's first approved drug for vitiligo repigmentation. Through the "Hong Kong and Macao Medicine and Equipment Connect" policy, ruxolitinib cream has been used in some designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area. It was approved by the Guangdong provincial government before its formal approval in China and has accumulated certain clinical experience in China. For this reason, a working group composed of experts from pharmacy, dermatology, and other disciplines has summarized the evidence-based medical evidence. They have also comprehensively considered the current diagnosis and treatment situation in China, as well as clinical practice experience, and formulated the Medical and Pharmaceutical Expert Consensus on Ruxolitinib Cream for Vitiligo. This consensus systematically elaborates on the mechanism of action, pharmacokinetics, clinical application, and safety management of ruxolitinib cream. After several rounds of expert discussions, revisions, and voting, five recommendations were finally formed to provide guidance for the clinical application of ruxolitinib cream.

ruxolitinib cream  /  vitiligo  /  JAK inhibitor  /  clinical application  /  expert consensus